Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.46 |
| ▸ | GSK3B | P49841 | 8/20 | 0.45 |
| ▸ | WNT1 | P04628 | 4/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614814 | 0.91 | ABL1 (0.49) | ABL1FGFR4DYRK1AMKNK2CDK8 | |
| SCHEMBL19307233 | 0.91 | ABL1 (0.49) | ABL1FGFR4DYRK1AMKNK2CDK8 | |
| SCHEMBL20227782 | 0.91 | ABL1 (0.47) | ABL1FGFR4DYRK1AGSK3BWNT1 | |
| SCHEMBL20214661 | 0.86 | ABL1 (0.46) | ABL1FGFR4MKNK2CDK8ABL2 | |
| SCHEMBL21350972 | 0.85 | ABL1 (0.42) | ABL1FGFR4DYRK1AMKNK2CDK8 | |
| SCHEMBL20227767 | 0.84 | ABL1 (0.46) | ABL1FGFR4MKNK2CDK8ABL2 | |
| SCHEMBL23732874 | 0.83 | ABL1 (0.44) | ABL1FGFR4MKNK2CDK8ABL2 | |
| SCHEMBL20227766 | 0.83 | ABL1 (0.46) | ABL1FGFR4MKNK2CDK8ABL2 | |
| SCHEMBL20214708 | 0.81 | ABL1 (0.45) | ABL1FGFR4MKNK2CDK8ABL2 | |
| SCHEMBL23732816 | 0.80 | ABL1 (0.53) | ABL1FGFR4MKNK2CDK8ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3548476-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | ABL1 1855/4885FGFR4 3830/4885DYRK1A 3563/4885 |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | ABL1 1855/4885FGFR4 3830/4885DYRK1A 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.